PD L1 News and Research

RSS

Prior treatment may impact efficacy of ACT-TIL in patients with metastatic melanoma

Patients with metastatic melanoma that had relapsed on anti-PD-1 therapies or BRAF/MEK inhibitors did not respond as well to an investigational therapy that involves the adoptive cell transfer of tumor-infiltrating lymphocytes (ACT-TIL) as patients naïve to these treatments.

19 Aug 2021

Nanotechnology may help improve treatment for colorectal cancer and melanoma

University of Arizona Health Sciences researchers recently completed a study that has the potential to improve cancer treatment for colorectal cancer and melanoma by using nanotechnology to deliver chemotherapy in a way that makes it more effective against aggressive tumors.

12 Aug 2021

New immunotherapy strategy can eliminate pancreatic tumors in mice

Pancreatic cancer, which affects about 60,000 Americans every year, is one of the deadliest forms of cancer. After diagnosis, fewer than 10 percent of patients survive for five years.

6 Aug 2021

Using circulating tumor DNA to detect urothelial cancer relapse could help improve treatment

Using circulating tumor DNA to identify patients at risk of urothelial cancer relapse after surgical resection could help improve post-surgery treatment.

6 Aug 2021

Researchers develop the most comprehensive molecular map of lung squamous cell carcinoma

Lung cancer remains the leading cause of cancer-associated death in the United States and worldwide. Patients with a subtype called lung adenocarcinoma (LUAD) have benefited from the development of new targeted medicines, but the search for effective new therapies for another subtype called lung squamous cell carcinoma (LSCC) has largely come up short.

5 Aug 2021

Study examines the role of programmed cell death ligands in skin immune responses

T cells are a crucial part of the human adaptive immune system. In response to a foreign invader in the body, various subsets of T cells are responsible for several functions that include killing infected cells and secreting signaling molecules called cytokines that tell other immune cells where to go and what to do.

29 Jul 2021

Biomarker shows potential to predict immunotherapy benefit for breast cancer patients

A biomarker that has proven to be a predictor for response to immunotherapies in melanoma patients also has clinical relevance for breast cancer patients, according to a new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

27 Jul 2021

Study shows promise of combining radiation therapy with dendritic-cell vaccines for breast cancer

A research team led by Fumito Ito, MD, PhD, FACS, of Roswell Park Comprehensive Cancer Center reports new data on the promise of combining standard treatment for breast cancer with a particular form of cancer immmunotherapy -; dendritic-cell (DC) treatment vaccines.

20 Jul 2021

Drug combination found to be safe and effective in malignant peritoneal mesothelioma patients

A phase II study led by researchers from The University of Texas MD Anderson Cancer Center found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response rate in patients with advanced malignant peritoneal mesothelioma, a rare cancer in the lining of the abdomen.

14 Jul 2021

Scientists discover potential marker for the success of immunotherapy in lung cancer patients

Lung cancer has the highest mortality rate of all cancers, and treatment options are extremely limited, especially for patients with oncogenic mutations in the KRAS gene.

8 Jul 2021

Lung cancer patients should be screened for MET oncogene amplification, research suggests

Research by investigators at Mayo Clinic Cancer Center suggests that physicians should screen patients with lung cancer for MET amplification/overexpression before determining a treatment strategy.

1 Jul 2021

AMSBIO offers an extensive collection of normal and disease state FFPE tissue blocks

AMSBIO has established an unmatched commercial biorepository and procurement network that includes a large selection of fully characterized and annotated Formalin-Fixed Paraffin-Embedded tissue blocks to help streamline your research.

From AMS Biotechnology 1 Jul 2021

UTHSC researchers publish new findings on how obesity impacts cancer treatments

Liza Makowski, PhD, professor in the Department of Medicine and the UTHSC Center for Cancer Research, has long been interested in how the immune system is altered by obesity and how this impacts cancer risk and treatment.

25 Jun 2021

Study: A subset of patients with localized prostate cancer may benefit from immunotherapies

In recent years, cancer immunotherapy has been effective in treating patients with immunogenic, or so-called "hot" tumors with increased levels of inflammation and the presence of immune cells in and around the tumors.

24 Jun 2021

CU Cancer Center secures unique SPORE grant for head and neck cancer research

Research and treatment of head and neck cancers at the University of Colorado Cancer Center reached a new level this month with a highly competitive Specialized Programs of Research Excellence grant from the National Cancer Institute.

21 Jun 2021

Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit

Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary.

18 Jun 2021

PET/CT images can be used to measure biomarker levels, predict lung cancer outcomes

Tests that analyze biomarkers are used during cancer management to guide treatment and provide information about patient prognosis.

17 Jun 2021

Artificial intelligence for predicting TMB-H colorectal cancer from histopathological characteristics

Biomarkers are important determinants of appropriate and effective therapeutic approaches for various diseases including cancer.

14 Jun 2021

Vagus nerve stimulation may be a potential adjunct therapy for COVID-19

COVID-19 was initially described as lung inflammation, or pneumonia, in older adults. However, we now know that SARS-CoV-2 infections can cause a wide range of symptoms in people of all ages, ranging from no symptoms at all to systemic inflammation and even death.

27 May 2021

Aberrant immune features in healthy elderly and male subjects with severe COVID-19 may predate infection

A new study shows that the immunological features of severe COVID-19 are already present in healthy older adults and in men, before they are infected, indicating a possible explanation for this differential susceptibility towards the virus.

6 May 2021